Nasal Spray Breakthrough: Study Shows Potential to Slow Alzheimer’s Disease Progression in Mice
A strong link exists between Alzheimer’s disease and insulin resistance. This connection has led researchers to refer to Alzheimer’s as type III diabetes. An innovative nasal spray developed by Italian researchers has shown promise in slowing brain deterioration in mice at risk of Alzheimer’s-like conditions.
The study, led by Francesca Natale from the Catholic University of Milan, identified a key enzyme called S-acyltransferase. This enzyme appears in higher levels in the brains of Alzheimer’s patients. Previous research indicates that insulin resistance can affect the amount of S-acyltransferase in the brain. This enzyme attaches fatty acids to beta-amyloid and tau proteins, which form clumps associated with Alzheimer’s. When insulin resistance occurs, these processes may malfunction.
In this study, the researchers disabled S-acyltransferase in mice genetically modified to exhibit Alzheimer’s-like symptoms. They found that symptoms lessened, and neurodegeneration slowed down. The lifespan of these mice also increased. Normal mice did not show these effects when given the same treatment.
The nasal spray uses an active agent called 2-bromopalmitate. This agent could interfere with various body processes, making it currently unsafe for human trials. However, researchers are optimistic about finding a safer alternative now that they have identified S-acyltransferase as a target.
What is the connection between insulin resistance and Alzheimer’s disease as discussed by Dr. Francesca Natale?
Interview with Dr. Francesca Natale on a Promising Nasal Spray for Alzheimer’s Disease
NewsDirectory3.com: Today, we’re speaking with Dr. Francesca Natale from the Catholic University of Milan, the lead researcher behind a groundbreaking study that connects insulin resistance to Alzheimer’s disease and explores an innovative nasal spray treatment. Welcome, Dr. Natale!
Dr. Natale: Thank you for having me.
NewsDirectory3.com: Your research has identified a significant link between Alzheimer’s and insulin resistance, which you refer to as type III diabetes. Can you elaborate on this connection?
Dr. Natale: Yes, absolutely. Our findings indicate that insulin resistance may play a critical role in the accumulation of toxic proteins in the brain, such as beta-amyloid and tau. These proteins clump together, leading to neurodegeneration characteristic of Alzheimer’s. We found that a specific enzyme, S-acyltransferase, is present in higher levels in the brains of Alzheimer’s patients and can be influenced by insulin resistance.
NewsDirectory3.com: Intriguingly, your study involved genetically modified mice to explore the effects of inhibiting S-acyltransferase. What were your key findings?
Dr. Natale: By disabling S-acyltransferase in these mice, we observed a significant reduction in Alzheimer’s-like symptoms. Neurodegeneration was notably slowed, and even the lifespan of these mice increased compared to normal mice, which suggests a direct link between the enzyme’s activity and the disease’s progression.
NewsDirectory3.com: You developed a nasal spray utilizing an active ingredient called 2-bromopalmitate. What makes this approach innovative, and what are the current limitations?
Dr. Natale: The nasal spray is designed to deliver the active agent directly to the brain, circumventing the blood-brain barrier. While this approach shows promise, 2-bromopalmitate could disrupt various metabolic processes, so it’s currently deemed unsafe for human trials. However, identifying S-acyltransferase as a target gives us a solid foundation to seek safer alternatives.
NewsDirectory3.com: Given the urgent need for effective Alzheimer’s treatments—diagnoses are made every three seconds—what are the next steps for your research?
Dr. Natale: We plan to explore other therapeutic options, such as genetic patches and engineered proteins to inhibit S-acyltransferase without the risks associated with our current active agent. Our ultimate goal is to develop a safe and effective treatment that could significantly delay or even prevent the onset of Alzheimer’s.
NewsDirectory3.com: Your study also touches on the dual nature of beta-amyloid protein clumps in relation to brain health. Can you clarify this point?
Dr. Natale: Certainly! Recent studies suggest that beta-amyloid aggregates can both contribute to brain damage and, interestingly, might not directly injure brain tissues depending on other molecular interactions at play. This complexity emphasizes the need for targeted therapies that can address these nuanced relationships.
NewsDirectory3.com: Thank you, Dr. Natale, for your insights and updates on this critical area of research. We look forward to following your work as it progresses.
Dr. Natale: Thank you for the opportunity. I’m optimistic about the future of Alzheimer’s research and the potential advancements we can make for those affected by this disease.
More research is necessary to evaluate the safety of this approach. Current trends show a new dementia diagnosis occurring every three seconds, highlighting the urgent need for effective treatments. Researchers plan to explore new therapeutic options, including genetic patches and engineered proteins that may disrupt S-acyltransferase activity.
The findings from this study align with recent research indicating that beta-amyloid protein clumps may both contribute to and not directly harm brain tissues, depending on other molecules present. The study indicates that S-acyltransferase has not been targeted therapeutically in Alzheimer’s disease. Thus, this research enhances our understanding of Alzheimer’s and highlights potential treatment targets.
This research was published in PNAS.